Tags

Type your tag names separated by a space and hit enter

Effect of ozagrel (OKY-046), a thromboxane synthetase inhibitor, on theophylline pharmacokinetics in asthmatic patients.

Abstract

The effect of ozagrel (OKY-046), a selective thromboxane A2 synthetase inhibitor, on theophylline disposition was studied in 12 asthmatic patients. Ozagrel was administered at a dose of 200 mg twice daily for 24 weeks to 4 outpatients receiving oral theophylline medication. Blood samples were drawn from each patient visiting the hospital at one to four-week intervals. There were no clinical significant changes between the time course profiles of serum theophylline concentration during the treatment and those after the cessation of ozagrel dosing. In addition, another 8 hospitalized patients received a single intravenous infusion of aminophylline (200 mg as theophylline) before and after ozagrel treatment of 200 mg twice daily for 7 days. No statistical significant alteration in elimination half-life, total body clearance or volume of distribution of theophylline was observed by the administration of ozagrel. These results suggest that ozagrel does not inhibit the metabolism of theophylline despite having an imidazole ring in its chemical structure.

Authors+Show Affiliations

Department of Hospital Pharmacy, Kyoto University, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2338368

Citation

Kawakatsu, K, et al. "Effect of Ozagrel (OKY-046), a Thromboxane Synthetase Inhibitor, On Theophylline Pharmacokinetics in Asthmatic Patients." International Journal of Clinical Pharmacology, Therapy, and Toxicology, vol. 28, no. 4, 1990, pp. 158-63.
Kawakatsu K, Kino T, Yasuba H, et al. Effect of ozagrel (OKY-046), a thromboxane synthetase inhibitor, on theophylline pharmacokinetics in asthmatic patients. Int J Clin Pharmacol Ther Toxicol. 1990;28(4):158-63.
Kawakatsu, K., Kino, T., Yasuba, H., Kawaguchi, H., Tsubata, R., Satake, N., & Oshima, S. (1990). Effect of ozagrel (OKY-046), a thromboxane synthetase inhibitor, on theophylline pharmacokinetics in asthmatic patients. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 28(4), pp. 158-63.
Kawakatsu K, et al. Effect of Ozagrel (OKY-046), a Thromboxane Synthetase Inhibitor, On Theophylline Pharmacokinetics in Asthmatic Patients. Int J Clin Pharmacol Ther Toxicol. 1990;28(4):158-63. PubMed PMID: 2338368.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of ozagrel (OKY-046), a thromboxane synthetase inhibitor, on theophylline pharmacokinetics in asthmatic patients. AU - Kawakatsu,K, AU - Kino,T, AU - Yasuba,H, AU - Kawaguchi,H, AU - Tsubata,R, AU - Satake,N, AU - Oshima,S, PY - 1990/4/1/pubmed PY - 1990/4/1/medline PY - 1990/4/1/entrez SP - 158 EP - 63 JF - International journal of clinical pharmacology, therapy, and toxicology JO - Int J Clin Pharmacol Ther Toxicol VL - 28 IS - 4 N2 - The effect of ozagrel (OKY-046), a selective thromboxane A2 synthetase inhibitor, on theophylline disposition was studied in 12 asthmatic patients. Ozagrel was administered at a dose of 200 mg twice daily for 24 weeks to 4 outpatients receiving oral theophylline medication. Blood samples were drawn from each patient visiting the hospital at one to four-week intervals. There were no clinical significant changes between the time course profiles of serum theophylline concentration during the treatment and those after the cessation of ozagrel dosing. In addition, another 8 hospitalized patients received a single intravenous infusion of aminophylline (200 mg as theophylline) before and after ozagrel treatment of 200 mg twice daily for 7 days. No statistical significant alteration in elimination half-life, total body clearance or volume of distribution of theophylline was observed by the administration of ozagrel. These results suggest that ozagrel does not inhibit the metabolism of theophylline despite having an imidazole ring in its chemical structure. SN - 0174-4879 UR - https://www.unboundmedicine.com/medline/citation/2338368/Effect_of_ozagrel__OKY_046__a_thromboxane_synthetase_inhibitor_on_theophylline_pharmacokinetics_in_asthmatic_patients_ L2 - https://medlineplus.gov/asthma.html DB - PRIME DP - Unbound Medicine ER -